Roche Hedges On U.S. Launch Of Mircera With November FDA Action Date Expected
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision in Amgen’s patent infringement case against Roche over the continuous erythropoiesis receptor activator is expected in October.